

This newsletter summarises final decisions from HTA bodies around the world from November 2023.

These decisions are categorised into one of four groups.

- Statements from HTA bodies in the form of guidelines on the management of a disease using specific interventions are included under Other Guidance.
- Decisions of HTA bodies are categorised according to the type of intervention into Pharmacological, Non-Pharmacological and Diagnostic.

Click on the category you are interested in to jump to that section

[Pharmacological Technologies](#)

[Non-pharmacological Technologies](#)

[Diagnostic Tests](#)

[Other Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter:



The reporting document states that the technology has been approved.



The reporting document states that the technology has not been approved.



The report was terminated, additional details are provided under the icon.



The report was excluded because it is covered by another HTA body in that country.



This is where documentation cannot be translated or it is unclear on the reporting outcome.



This entry includes a note from the report relating to the technology.



This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies



Blood

- [Eftrenonacog alfa - Germany](#)
- [Epoetin alfa - Brazil](#)
- [Hydroxyurea 100mg and 1000mg - Brazil](#)
- [Hydroxyurea 100mg and 1000mg - Brazil](#)
- [Hydroxyurea 500mg - Brazil](#)
- [Mepolizumab - Brazil](#)
- [Ravulizumab - Brazil](#)



Cancer


- [Cabozantinib - England](#)
- [Decitabine–cedazuridine - England](#)
- [Dostarlimab - Austria](#)
- [Durvalumab - Wales](#)
- [Durvalumab - Brazil](#)
- [Durvalumab - Scotland](#)
- [Durvalumab - Austria](#)
- [Elranatamab - Austria](#)
- [Glofitamab - Germany](#)
- [Idecabtagene vicleucel - England](#)
- [Lisocabtagen maraleucel - Germany](#)
- [Loncastuximab tesirine - Germany](#)
- [Lutetium-177 vipivotide tetraxetan - England](#)
- [Nivolumab - Germany](#)
- [Pembrolizumab - Austria](#)
- [Pembrolizumab - Brazil](#)
- [Rucaparib - Austria](#)
- [Sacituzumab bigovitecan - Finland](#)

Cancer




- [Sacituzumab govitecan - Germany](#)
- [Selpercatinib - Scotland](#)
- [Tisagenlecleucel - England](#)
- [Trastuzumab deruxtecan - Finland](#)
- [Trifluridine/tipiracil - Germany](#)
- [Zanubrutinib - England](#)
- [Zanubrutinib - Austria](#)

Cardiovascular



- [Avacopan - Scotland](#)
- [Empagliflozin - England](#)
- [Human plasma-derived C1 esterase inhibitor - Brazil](#)
- [Icatibant acetate - Brazil](#)
- [Mavacamten - Germany](#)
- [Subcutaneous plasma-derived C1 esterase inhibitor - Brazil](#)

Gastrointestinal



- [Infliximab - Brazil](#)
- [Risankizumab - Scotland](#)

Genitourinary



- [Empagliflozin - Germany](#)
- [Mercaptamine - Scotland](#)

Genetic/Metabolic



- [Cipaglucosidase alfa - Germany](#)
- [Migalastat - Germany](#)
- [Pegunigalsidase alfa - Scotland](#)
- [Tafamidis - Scotland](#)

Pharmacological Technologies



Infection

- Bedaquiline - Germany
- Nirmatrelvir & Ritonavir - Brazil
- Tixagevimab/ cilgavimab - Germany



Musculoskeletal

- Bimekizumab - Scotland



Pregnancy

- Progesterone vaginal capsules - Scotland




Neurology

- Efgartigimod alfa - Scotland
- Foslevodopa-foscarbidopa - England
- Omaveloxolone - France



Respiratory

- Mepolizumab and Benralizumab - Finland
- Omalizumab - Brazil



Skin


- Dalbavancin - Germany

Non-pharmacological Technologies



Cancer

- Ultra-hypofractionated adjuvant radiotherapy - Ireland




Cardiovascular

- Percutaneous thrombectomy - England
- Percutaneous transarterial carotid artery stent placement - England



Mental health

- Virtual reality technologies - England



Musculoskeletal

- Biodegradable subacromial spacer - England



Respiratory

- Extracorporeal carbon dioxide removal - England



Surgery

- Symani Surgical System microanastomosis robot - Finland

Other


- Needleless jet injection - South Korea

Diagnostic Technologies



Cancer

- [\(18F\)_piflufolastat - France](#)
- [FGFR companion diagnostic test \(real-time PCR\) - South Korea](#)



Cardiovascular

- [Coronary computed tomography angiography - South Korea](#)
- [Pulse oximetry - South Korea](#)



Mental health


- [Sasang Personality Questionnaire - South Korea](#)

Other Guidance



Cancer

- [Artificial Intelligence - Spain](#)
- [ESMO-Magnitude of Clinical Benefit Scale - Singapore](#)
- [Intrathecal Drug Delivery - Canada](#)
- [Supplemental Screening Modalities - Canada](#)



Cardiovascular

- [Inclisiran - Singapore](#)
- [Transcatheter Aortic Valve Implantation \(TAVI\) - Singapore](#)
- [Transcatheter mitral valve leaflet repair \(TMVLR\) - Singapore](#)



Eye

- [Anti-VEGF drugs - Canada](#)
- [Intraocular lenses - Canada](#)



Genetic/Metabolic

- [Spinal muscular atrophy \(SMA\) - Ireland](#)



Infection

- [Molnupiravir - Singapore](#)
- [Mupirocin nasal ointment - Norway](#)



Mental health

- [Flow transcranial direct current stimulation - England](#)
- [Interventions for mental health - Spain](#)

Neurology

- [Neuromuscular feedback therapy - Germany](#)



Surgery

- [Case carts - Canada](#)




Other

- [Buprenorphine-naloxone film - Canada](#)
- [HTA framework - Spain](#)
- [Pharmacotherapy - United States](#)
- [Routine Dental Polishing - Canada](#)
- [Stockpiling of medical countermeasures - Ireland](#)

Musculoskeletal

- [Different treatments for cervical degenerative disease - United States](#)



Pharmacological Technologies



Blood

Germany



Eftrenonacog alfa

For haemophilia B.

IQWiG - A23-77



Population:
Adult, Adolescent
and Children

02 November 2023

Brazil



Epoetin alfa

Population:
Unknown
Patients showing
decline in kidney
function and
worsening of
haemoglobin levels

01 November 2023

For sickle cell disease.

CONITEC



Recommended for public
consultation with a
favourable opinion.

Brazil



Hydroxyurea 100mg
and 1000mg

For the prevention of
painful vaso-occlusive
crises in sickle cell
syndrome.

CONITEC



Recommended for public
consultation with a favourable
opinion (100 mg)/
unfavourable (1000 mg).

Population:
Adult, Adolescent
and Children
From 2 years of age

01 November 2023

Brazil



Hydroxyurea 100mg
and 1000mg

For sickle cell disease.

CONITEC



Recommended for public
consultation with a favourable
opinion (100 mg)/
unfavourable (1000 mg).

Population:
Adult, Adolescent
and Children
From 9 months of
age

01 November 2023

Pharmacological Technologies



Blood

Brazil



For sickle cell disease
(SS, Sbeta0 and SD
Punjab).

Hydroxyurea 500mg

Population:
Children
Between 9 and 24
months of age

01 November 2023

CONITEC



Recommended for public
consultation with a
favourable opinion.

Brazil



Mepolizumab

Population:
Children and
Adolescent
Between 6 and 17
years of age

08 November 2023

CONITEC



Recommended for public
consultation with an
unfavourable opinion.

Brazil



Ravulizumab

Population:
Adult and
Adolescent
From 14 years of age

09 November 2023

For nocturnal
paroxysmal
haemoglobinuria (NPH).

CONITEC



Recommended for public
consultation with an
unfavourable opinion.

Pharmacological Technologies



Cancer

<p>England</p>  <p>Cabozantinib</p> <p>Population: Adult</p> <p>01 November 2023</p>	<p>For relapsed/recurrent advanced differentiated thyroid cancer.</p> <p><i>NICE - TA928</i></p> <p>NOT APPROVED</p>	<p>England</p>  <p>Decitabine–cedazuridine</p> <p>Population: Adult</p> <p>23 November 2023</p>	<p>For untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.</p> <p><i>NICE - TA932</i></p> <p>TERMINATED</p> <p>No submission made</p>
<p>Austria</p>  <p>Dostarlimab</p> <p>Population: Adult Candidates for systemic therapy</p> <p>17 November 2023</p>	<p>For dMMR/ MSI-H primary advanced or recurrent endometrial cancer.</p> <p><i>AIHTA - 1482</i></p> <p>APPROVED</p> <p>Approved by CHMP. EMA approved, FDA approved.</p>	<p>Wales</p>  <p>Durvalumab</p> <p>Population: Unknown</p> <p>15 November 2023</p>	<p>For unresectable or advanced biliary tract cancer.</p> <p><i>AWTTC - 5018</i></p> <p>EXCLUDED</p> <p>Due to NICE appraisal ID4031</p>

Pharmacological Technologies



Cancer

Brazil



Durvalumab

For stable unresectable stage III NSCLC.

CONITEC

Population:
Unknown



Recommended for public consultation with an unfavourable opinion.

08 November 2023

Scotland



Durvalumab

For newly-diagnosed locally advanced, unresectable, or metastatic biliary tract cancer.

SMC - SMC2582

Population:
Adult



13 November 2023

Austria



Durvalumab

For treatment-naive advanced or unresectable hepatocellular carcinoma.

AIHTA - 1481

Population:
Adult



Approved by CHMP. EMA approved, not FDA approved.

17 November 2023

Austria



Elranatamab

For refractory or relapsed multiple myeloma.

AIHTA - 1480

Population:
Adult



Approved by CHMP. EMA approved, not FDA approved.

17 November 2023

Pharmacological Technologies



Cancer

<p>Germany</p>  <p>Glofitamab</p> <p>Population: Unknown</p> <p>02 November 2023</p>	 <p>For diffuse large B-cell lymphoma.</p> <p><i>IQWiG - G23-17</i></p> <p> APPROVED</p> <p>Orphan Drug Status</p>	<p>England</p>  <p>Idecabtagene vicleucel</p> <p>Population: Adult</p> <p>30 November 2023</p>	 <p>For relapsed and refractory multiple myeloma after 3 or more treatments.</p> <p><i>NICE -TA936</i></p> <p> TERMINATED</p> <p>No submission made</p>
<p>Germany</p>  <p>Lisocabtagen maraleucel</p> <p>Population: Adult</p> <p>17 November 2023</p>	 <p>For relapsed/refractory DLBCL, HBGCL, PMBCL and FL3B.</p> <p><i>IQWiG - A23-48</i></p> <p> APPROVED</p>	<p>Germany</p>  <p>Loncastuximab tesirine</p> <p>Population: Adult</p> <p>17 November 2023</p>	 <p>For relapsed/refractory DLBCL and HMBCL.</p> <p><i>IQWiG - A23-45</i></p> <p> NOT APPROVED</p>

Pharmacological Technologies



Cancer

England



Lutetium-177

vipivotide tetraxetan

For relapsed/refractory PSMA-positive hormone-relapsed metastatic prostate cancer.

NICE - TA930



Population:
Adult

15 November 2023

Germany



Nivolumab

Population:
Adult
Adults at high risk of recurrence

02 November 2023

Neoadjuvant treatment of NSCLC.

IQWiG - A23-74



Austria



Pembrolizumab

For treatment-naive locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.

AIHTA - 1483



Approved by CHMP. EMA approved, not FDA approved.

Population:
Adult

17 November 2023

Brazil



Pembrolizumab

Population:
Unknown

01 November 2023

For treatment-naive advanced or metastatic PD-L1 NSCLC.

CONITEC



Pharmacological Technologies



Cancer

Austria



Rucaparib

For maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

AIHTA - 1484



Approved by CHMP. EMA approved, not FDA approved.

17 November 2023

Population:
Adult

Finland



Sasituzumab bigovitecan

For relapsed/refractory advanced or locally advanced HR+/HER2 breast cancer.

FINCCTA



Population:
Unknown

November 2023

Germany



Sacituzumab govitecan

For relapsed/refractory unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer.

IQWiG - A23-86



Population:
Adult

15 November 2023

Scotland



Selpercatinib

For advanced RET fusion-positive NSCLC.

SMC - SMC2573



Population:
Adult

13 November 2023

Restricted approval

Pharmacological Technologies



Cancer

England



Tisagenlecleucel

For relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies.

NICE - TA933



Withdrawn

Population:
Adult

29 November 2023

Finland



Trastuzumab
deruxtecan

For relapsed/refractory metastatic HER2 1+ or 2+ and ISH negative HER2 low breast cancer.

FINCCTA



Population:
Unknown

November 2023

Germany



Trifluridine/tipiracil

For relapsed/refractory metastatic colorectal cancer, in combination with bevacizumab.

IQWiG - A23-85




Population:
Adult

15 November 2023

Pharmacological Technologies



Cancer



Cardiovascular

England



Zanubrutinib

For chronic lymphocytic leukaemia.

NICE - TA931

Population:
Adult



Restricted approval

22 November 2023

Scotland



Avacopan

For severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

SMC - SMC2578

Population:
Adult



13 November 2023

Austria



Zanubrutinib

For relapsed/refractory follicular lymphoma, with obinutuzumab.

AIHTA - 1479

Population:
Adult



Approved by CHMP. EMA approved, not FDA approved.

17 November 2023

England



Empagliflozin

For chronic heart failure with preserved or mildly reduced ejection fraction.


NICE - TA929

Population:
Adult



01 November 2023

Pharmacological Technologies



Cardiovascular

Brazil



For acute attacks in hereditary angioedema.

Human plasma-derived C1 esterase inhibitor

Brazil



For acute attacks in C1 esterase inhibitor deficiency (types I and II) hereditary angioedema.

Icatibant acetate

CONITEC

CONITEC

Population:
Adult, Adolescent
and Children
From 2 years of age

Population:
Adult



09 November 2023

09 November 2023

Germany



For symptomatic (NYHA class II – III) hypertrophic obstructive cardiomyopathy.

Mavacamten

Brazil



For the prophylaxis of seizures in hereditary angioedema.

Subcutaneous plasma-derived C1 esterase inhibitor

IQWiG - A23-76

CONITEC

Population:
Adult


Population:
Unknown



02 November 2023

09 November 2023

Pharmacological Technologies



Gastrointestinal



Genitourinary

Brazil



Infliximab

For refractory moderate to severe Crohn's disease.

CONITEC

Population:
Adult

08 November 2023



Recommended for public consultation with an unfavourable opinion.

Germany



Empagliflozin

Population:
Adult
Chronic renal
insufficiency

02 November 2023

For renal insufficiency.

IQWiG - A23-79



Scotland



Risankizumab

For refractory moderately to severely active Crohn's disease.

SMC - SMC2534

Population:
Adult and
Adolescent
Patients 16 years of
age or older

13 November 2023



Scotland



Mercaptamine

Population:
Unknown

13 November 2023

For proven nephropathic cystinosis.

SMC - SMC2571



Pharmacological Technologies



Genetic/Metabolic

Germany



Cipaglucosidase alfa

Population:
Adult

02 November 2023

For Pompe's disease.

IQWiG - A23-79

NOT APPROVED

Germany



Migalastat

Population:
Adult and
Adolescent
Patients 12 years of
age or older


15 November 2023

For Fabry disease in the presence of a mutation that is responsive to treatment.

IQWiG - A23-88

NOT APPROVED

Scotland



Pegunigalsidase alfa

Population:
Adult

13 November 2023

For Fabry disease.

SMC - SMC2591

NOT APPROVED

Scotland



Tafamidis

Population:
Adult
Patients with
cardiomyopathy


13 November 2023

For wild-type and hereditary transthyretin amyloidosis.

SMC - SMC2585

APPROVED


Pharmacological Technologies



Infection

<p>Germany</p>  <p>Bedaquiline</p> <p>Population: Unknown</p> <p>02 November 2023</p>	 <p>For tuberculosis.</p> <p><i>IQWiG - G23-18</i></p> <p> APPROVED</p> <p>Orphan Drug Status</p>	<p>Brazil</p>  <p>Nirmatrelvir & Ritonavir</p> <p>Population: Unknown High-risk</p> <p>01 November 2023</p>	 <p>For COVID-19.</p> <p><i>CONITEC</i></p> <p> NOTE FROM REPORT</p> <p>Recommended for public consultation with a favourable opinion.</p>
<p>Germany</p>  <p>Tixagevimab/ cilgavimab</p> <p>Population: Adult and Adolescent Patients 12 years of age or older</p> <p>02 November 2023</p>	 <p>For prophylaxis of COVID-19.</p> <p><i>IQWiG - A23-42</i></p> <p> NOT APPROVED</p>		

Pharmacological Technologies



Musculoskeletal


Scotland



Bimekizumab

Population:
Adult

13 November 2023



For refractory active psoriatic arthritis, alone or in combination with methotrexate.

SMC - SMC2605



Restricted approval



Pregnancy


Scotland



Progesterone vaginal capsules

Population:
Adult
Women who have a short cervix and/or a history of spontaneous preterm birth.

13 November 2023



For prevention of preterm birth.

SMC - SMC2630



Pharmacological Technologies



Neurology

Scotland



Efgartigimod alfa

Population:

Adult
Patients who are
anti-acetylcholine
receptor (AChR)
antibody positive

13 November 2023

For generalised
myasthenia gravis
(gMG).

SMC - SMC2561



England



Foslevodopa-
foscarbidopa

Population:

Adult
Symptomatic of
severe motor
fluctuations and
hyperkinesia or
dyskinesia

29 November 2023

For advanced
Parkinson's with motor
symptoms.

NICE - TA934



Restricted approval

France



Omaveloxolone

Population:

Adult and
Adolescent
16 years of age or
older

16 November 2023

For Friedrich's Ataxia.

HAS - AP255




Early access authorisation

Pharmacological Technologies



Respiratory



Skin

Finland



Mepolizumab and
Benralizumab

For eosinophilic
pneumonia or
bronchopulmonary
aspergillosis.

FINCCTA

Population:
Unknown



November 2023

Germany



Dalbavancin

For acute bacterial skin
and soft tissue
infections.

IQWiG - G23-19

Population:
Unknown



02 November 2023

Orphan Drug Status

Brazil



Omalizumab

For uncontrolled severe
allergic asthma.

CONITEC

Population:
Unknown




Recommended for public
consultation with a
favourable opinion.

08 November 2023

Non-pharmacological Technologies



Cancer



Cardiovascular

Ireland



Ultra-hypofractionated adjuvant radiotherapy

For breast cancer.

HIQA



Population:
Adult

24 November 2023

England



Percutaneous thrombectomy

For intermediate-risk or high-risk pulmonary embolism.

NICE - IPG778



Population:
Unknown

29 November 2023

Restricted approval

England



Percutaneous transarterial carotid artery stent placement

For asymptomatic extracranial carotid stenosis.

NICE - IPG777



Population:
Unknown

22 November 2023

Restricted approval

Non-pharmacological Technologies



Mental Health



Musculoskeletal

England



Virtual reality technologies

For agoraphobia or agoraphobic avoidance.

NICE - HTE15

Population:
Adult



15 November 2023

England



Biodegradable subacromial spacer

For rotator cuff tears.

NICE - IPG775

Population:
Unknown



15 November 2023

Non-pharmacological Technologies



Respiratory

England



Extracorporeal
carbon dioxide
removal

For acute respiratory
failure.

NICE - IPG776



Population:
Adult

15 November 2023



Surgery

Finland



Symani Surgical
System
microanastomosis
robot

For reconstructive
microsurgery involving
blood vessel, nerve, or
lymphatic anastomosis.

FINCCTA



Population:
Unknown

November 2023

Non-pharmacological Technologies

Other

South Korea



Needleless jet
injection

Population:
Unknown

November 2023



For patients who require
subcutaneous or
intramuscular injection,
or oral anesthesia.


NECA - 1016



Diagnostic Technologies



Cancer



Cardiovascular

France



(18F) piflufolastat

For the detection of positive prostate-specific membrane antigen (PSMA) lesions by positron emission tomography (PET).

HAS - AP275

Population:
Adult



Early access authorisation

16 November 2023

South Korea



Coronary computed tomography angiography

For the Fractional Flow Reserve Measurement of Coronary Arteries.

NECA - 1020

Population:
Unknown



November 2023

South Korea



FGFR companion diagnostic test (real-time PCR)

For urothelial cancer.

NECA - 1019

Population:
Unknown



November 2023

South Korea



Pulse oximetry

Screening for severe congenital heart disease.

NECA - 1018

Population:
Children
Newborns



November 2023

Diagnostic Technologies



Mental Health

South Korea



Sasang Personality
Questionnaire

Population:
Unknown

November 2023



For the diagnosis and monitoring of patients with (suspected) mental disorders related to behavioral, cognitive, and emotional disorders.

NECA - 1017



Other Guidance



Cancer

Spain



Artificial Intelligence

For the detection and characterisation of colorectal precancerous lesions in colonoscopy.

AQuAS

Population:
Adult



November 2023

Singapore



ESMO-Magnitude of Clinical Benefit Scale

To evaluate the value of cancer medicines.

ACE

Population:
Unknown



November 2023

Canada



Intrathecal Drug Delivery

For the management of cancer pain.

CADTH - HC0058-000

Population:
Adult and Children



06 November 2023

Canada



Supplemental Screening Modalities

For the improvement of cancer detection.


CADTH - HC0026-000

Population:
Unknown



01 November 2023

Other Guidance



Cardiovascular

Singapore



Inclisiran

As an add-on therapy to standard-of-care for the prevention of cardiovascular events.

ACE



Population:
Unknown

November 2023

Singapore



Transcatheter Aortic Valve Implantation (TAVI)

For the treatment of symptomatic severe aortic stenosis.

ACE



Population:
Adult

November 2023

Singapore



Transcatheter mitral valve leaflet repair (TMVLR)

For treatment of grade 3 or 4 (moderate-to-severe or severe) mitral regurgitation, when ineligible for surgery.

ACE



Population:
Unknown

November 2023

Other Guidance



Eye



Genetic/Metabolic

Canada



Anti-VEGF drugs

For treatment of wet age-related macular degeneration.

CADTH - RC1510-000

Population:
Adult



Rapid review with
summary of
recommendations

06 November 2023

Ireland



Spinal muscular atrophy (SMA)

Addition to the National Newborn Bloodspot Screening Programme.

HIQA

Population:
Children
Newborns



27 November 2023

Canada



Intraocular lenses

For use in astigmatism.

CADTH - RC1515-000

Population:
Unknown



Rapid review with
summary of
recommendations

06 November 2023

Other Guidance



Infection

Singapore



Molnupiravir

For the treatment of
mild-to-moderate
COVID-19.

ACE

Population:
Unknown



November 2023



Mental Health

England



Flow transcranial
direct current
stimulation

For the treatment of
depression.

NICE - MIB324

Population:
Adult
18 years of age or
older



08 November 2023

Norway



Mupirocin nasal
ointment

As infection prevention
prophylaxis prior to
orthopaedic prosthesis
surgery.

NIPH

Population:
Unknown



10 November 2023

Spain



Interventions for
mental health

To improve well-being,
emotional health and
mental health.

AQuAS

Population:
Unknown



November 2023

Other Guidance



Neurology



Surgery

Germany



Neuromuscular
feedback therapy

For the treatment of
spinal cord injury.

IQWiG - E21-08

Population:
Unknown



22 November 2023

Canada



Case carts

Assessment of the
appropriate use of case
carts in surgical
settings.

CADTH - RC1512-000

Population:
Unknown




08 November 2023

Rapid review with
summary of
recommendations

Other Guidance

Other


Canada



Buprenorphine-naloxone film


Population:
Adult

06 November 2023




For treatment of opioid use disorder.

CADTH - RC1513-000



Rapid review with summary of recommendations


Spain



HTA framework


Population:
Unknown

November 2023



Methodological framework describing 13 domains, 41 dimensions, 9 subdimensions and 21 standards that should be consider in an HTA.

AQuAS




United States



Pharmacotherapy


Population:
Unknown

07 November 2023




For the treatment of alcohol use disorder.

AHRQ




Canada



Routine Dental Polishing


Population:
Adult and Children

08 November 2023



For the maintenance of oral health.

CADTH - RC1517-000



Rapid review with summary of recommendations

Other Guidance

Other



Musculoskeletal

Ireland



Stockpiling of
medical
countermeasures

In preparation for
emergencies such as
COVID-19.

HIQA



Population:
Unknown

24 November 2023

United States



Different treatments
for cervical
degenerative
disease

For the treatment of
cervical degenerative
disease.

AHRQ



Population:
Unknown

14 November 2023

About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk